Viral Load Reductions Persist With Less Efavirenz for HIV

[From Medscape, Pam Harrison, Nov 6, 2014] The virologic responses with reduced-dose efavirenz at 48 weeks have proven durable out to 96 weeks, ENCORE1 study results show.

The finding, presented at the HIV Drug Therapy Congress in Glasgow, United Kingdom, supports the use of a lower dose of the drug in combination with tenofovir plus emtricitabine as first-line therapy for HIV.

For the full article, click here.

Leave a Comment

Scroll to Top